Related Experiment Videos
Temporal lobe cytoarchitectural neuropathology in schizophrenia
1Dept. of Psychiatry, University of Wuerzburg, FRG.
Clinical Neuropharmacology
|January 1, 1992
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
Haemophilia : the official journal of the World Federation of Hemophilia·2016
BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
Haemophilia : the official journal of the World Federation of Hemophilia·2016
Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
Journal of thrombosis and haemostasis : JTH·2016
Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
Haemophilia : the official journal of the World Federation of Hemophilia·2016
Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
Journal of thrombosis and haemostasis : JTH·2014
Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.
Clinical neuropharmacology·2026
Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.
Clinical neuropharmacology·2026
A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.
Clinical neuropharmacology·2026
Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.
Clinical neuropharmacology·2026
Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.
Clinical neuropharmacology·2026
Neuregulin 4 in Insulin Resistance: Mechanisms, Controversies, and Therapeutic Perspectives.
Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Nanomedicine for targeting crosstalk between nerves and cancer.
Journal of controlled release : official journal of the Controlled Release Society·2026